Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Implants / Devices
    • MTaI suggests gradual...

    MTaI suggests gradual rollout of public procurement guidelines

    Written by Ruby Khatun Khatun Published On 2018-04-07T10:00:55+05:30  |  Updated On 7 April 2018 10:00 AM IST
    MTaI suggests gradual rollout of public procurement guidelines

    New Delhi: Medical Technology Association of India (MTaI), which represents leading research-based medical technology companies with significant investments in India, said the Department of Pharmaceuticals (DoP) should prepare a roadmap for implementation of its guidelines on public procurement in a phased manner to enable optimum patient access to advance medical devices.


    “Given that India’s medical devices regulatory regime is fairly new and its implementation is nascent, any preferential provisions for public procurement applied to all segments of devices will only limit patient access and forbid several kinds of medical technology that is not locally being produced. In view of the above, we strongly urge the Department of Pharmaceuticals to carve out a roadmap for a phased implementation of local content requirements in order to boost local manufacturing rather than imposing local content requirements where adequate ground work for promoting localization has not taken place,” MTaI said in the press release.


    The DoP had issued Draft Guidelines for Implementation of Public Procurement (Preference to Make in India) Order 2017 last month. It had asked for response from stakeholders before finalising the guidelines. In its response, MTaI has raised concerns on the implementation of preferential market access policy in the medical devices sector.


    “Make in India for medical devices is a long-drawn approach that will require calibrated steps for enhancement of local capacity of medical devices ranging from less advanced technology to most sophisticated ones.


    This journey also needs to be meticulously made organic with an identification of sub-segments where enough incentives and local resource pool lie and can be garnered with the country-specific capabilities, failing which disruptions in availability and accessibility of life-saving medical devices will only hamper patient access and jeopardize patient safety.


    MTaI would like to extend all support in working with the government to create a roadmap for realizing the goal for Make in India in medical devices.”


    At present, India has adequate manufacturing capabilities for products like syringes, cannulae, stop cocks, extension lines, blood bags, dressings, hospital furniture, and suction machines, but lacks the desired ecosystem for devices requiring complex research, design and engineering support, it added.


    “If the government feels the dire need to implement such preferential policy, it should exempt devices that are used in critical health conditions where quality and safety cannot be compromised,” the association said. “The government should also mandate requirement of 3-year market presence and verification of financial standing of bidders in order to ensure their credibility. In this, global standards of certification/quality management and product standards such as USFDA approval / CE mark/CDSCO standards should be adhered to,” it added.


    It is important to note that huge costs are incurred by innovation-based companies in ensuring safety and efficacy of medical devices and therefore these costs should be considered for calculating the percentage of local content, MTaI said.


    “The costs are being incurred on activities like R&D, cold chain management, and maintenance in India, which generate local employment and hence should be included in the calculation of local content,” the association added.


    MTaI said the government should also exempt all procurements by premium research institutes, teaching institutes, tertiary hospitals of Central or State Government such as AIIMS, SGPGI, PGIMER, SreeChitra, Army Research and Referral, Railways and Defense Departments from the purview of the order.


    “Since the basic objective of these research Institutes and hospitals is to train the clinicians on use of medical devices, new technologies and do research on new therapies, preferential procurement provisions for such institutions will limit their reach to most latest and cutting edge technology for want of local content,” MTaI said.

    AIIMSCDSCODepartment of PharmaceuticalsDOPdraft guidelinesGuidelinesMake in IndiaMedical DevicesMedical Technology Association of IndiaMTaIpublic procurement
    Source : Press Release

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok